Roska’s New Chief Creative Officer

Tina Fascetti joined Roska Healthcare Advertising as Executive Vice President and Chief Creative Officer. Fascetti previously worked with Roska as a consultant on several critical projects, and brings to her new role more than 20 years of experience managing agency-of-record relationships, product launches, customer experience programs and branding initiatives in the pharmaceutical and consumer industry. Prior to joining Roska, Fascetti held numerous senior-level, creative management positions at some of the world’s most respected advertising agencies. She was Executive Creative Director at Saatchi & Saatchi Health, SVP Worldwide Creative Director at GSW Worldwide, and VP Associate Creative Director at Sudler & Hennessey. Her work, and that of teams she led, has garnered numerous industry awards. She also appears frequently as a writer, speaker and thought leader in industry publications and events.

Superhero of Heart and Stroke

In honor of his efforts to raise awareness of heart disease and stroke prevention, Nick Colucci, president and CEO of Publicis Healthcare Communications Group, was named one of 11 Superheroes of Heart and Stroke by the American Heart Association (AHA) New York Affiliate.  The honorees were recognized at the New York City Heart Ball at the Intrepid Sea, Air and Space Museum. The Superheroes of Heart and Stroke are committed to helping fund research that produces results and saves lives. With Nick at the helm, PHCG has mobilized its agencies to support AHA initiatives, including the “Go Red for Women” campaign and “Wall Street Run and Heart Walk,” in addition to his service on the board of AHA New York Affiliate. “Nick is a man who walks the talk,” says Michael Weamer, executive vice president, AHA. “He has committed his personal time, and that of the agencies in his network, to creating awareness for the AHA here in New York with their creative efforts.”

Dudnyk

Dudnyk San Franciso has announced the appointment of Anthony Hall as Creative Director, Digital, and Kristen Dimmock as Account Supervisor. Hall has more than 16 years of professional experience in advertising digital design, including healthcare work with Alvine, Anacor, Anthera, PDL Biopharma, and Tensys Medical. Dimmock previously worked in London with Roche International on Zelboraf, the new blockbuster metastatic melanoma product and at Seven Stones, where she directed key launches, including Novartis products Gilenya and Lucentis.

inVentiv Health

inVentiv Health named Sydney Rubin Chief Communications Officer and Danielle DeForge Director of Corporate Communications. Rubin will oversee corporate reputation, internal communications, media relations and public affairs. Both previously held positions in the Chandler Chicco Companies, a part of inVentiv Health, where Rubin provided senior counsel in corporate reputation, content development, crisis communications and public affairs. DeForge has developed award-winning global media relations, public affairs and social media campaigns.

Kite Pharma

Kite Pharma, a clinical stage biotechnology company focused on cancer, named Keith Nolop, MD as Chief Medical Officer. Dr. Nolop was previously Senior VP of Development and Chief Medical Officer at Plexxikon, a member of the Daiichi Sankyo Group. While there, he was the clinical lead for the development of Zelboraf (vemurafenib), a first-in-class cancer drug co-developed with Hoffman-La Roche. Before joining Plexxikon, Dr. Nolop was Vice President of Clinical Research for CoTherix.

KnowledgePoint360

Marsha Caplin was named Vice President, Multichannel, by CircleScience, a division of KnowledgePoint360. After shaping the European and global online presence for Shell in the 1990s, Caplin moved to the pharmaceutical sector in 2004, where she has defined global digital communications strategies for a portfolio of oncology products using multi-channel approaches.

Optimer Pharmaceuticals

Optimer Pharmaceuticals appointed Eric Sirota as Chief Operating Officer. Sirota will be responsible for directing Optimer’s corporate strategy with regard to Dificid. Sirota previously served as a consultant to the company. In 2010, Sirota served as President of Commercial Services of inVentiv Health, where he developed strategies to address the need for integrated analytic, sales and marketing solutions that enhance brand revenue, drive efficiency and lower costs. Earlier he was Vice President of Pfizer’s U.S. Marketing, Commercial Strategy and Innovation and Regional Sales, responsible for the neuroscience and pain franchises.

Protagonist Therapeutics

Protagonist Therapeutics named David Y. Liu, PhD as Chief Scientific Officer. Dr. Liu was previously Chief Operating Officer and co-founder of Trenovus, as well as a strategic advisor to several other biotechnology companies. Before that he was a VP of Research and Corporate Officer at FibroGen, having management responsibility for all therapeutic research and drug discovery. Liu has been involved in the filing of 17 INDs and NDAs for over 10 clinical indications.

Quantitative Insights

Keith Tipton has joined Quantitative Insights as Chief Executive Officer. Tipton brings a rich background in computer-aided detection and diagnostic and therapy-related medical imaging devices to Quantitative Insights. His career spans 30 years in research, development and business management. Previously Tipton was founding member and head of research and development of Philips Women’s Healthcare, and before that general manager of Philips’ Radiation Therapy Planning division.

Regenesis Biomedical

Regenesis Biomedical, an emerging medical device company focused on pain management, named Scott Brooks Chief Executive Officer and member of the Board of Directors, succeeding Virginia Rybski. Previously, Brooks was President of BSN Medical and held senior executive positions at Kinetic Concepts, The Hill-Rom Company and Kimberly-Clark Health Care. His experience includes sales and marketing, business development, national accounts and operations.

Vocera

Vocera Communications appointed Brent D. Lang President and Chief Executive Officer. Lang previously served as President and Chief Operating Officer and succeeds Robert J. Zollars, who was appointed Executive Chairman of the Board. He began his tenure at Vocera in June 2001 as the company’s Vice President of Marketing and Business Development.

Ads

You May Also Like

Healthcare Watch April 2016

Med Device: Neurological Disease Detected by “Mini-brains” Mini-brains are clumps of neurons and cells ...